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Background: In order to promote widespread adoption of appropriate clinical practice, the Italian Society of
Hematology (SIE), and the afﬁliate societies SIES (Italian Society of Experimental Hematology) and GITMO (Italian Group
for Bone Marrow Transplantation) established to produce guidelines in the most relevant hematological areas. In this
article, we report the recommendations for management of T/NK-cell lymphomas, excluding mature T-cell leukaemias.
Design: By using the Grades of Recommendations, Assessment, Development and Evaluation (GRADE) system, we
produced evidence-based recommendations for the key clinical questions that needed to be addressed by a critical
appraisal of evidence. The consensus methodology was applied to evidence-orphan issues.
Results: Six courses of cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) or cyclophosphamide, doxo-
rubicin, vincristine, etoposide and prednisone (CHOEP) chemotherapy were recommended for ﬁrst-line therapy of patients
with nodal, intestinal or hepatosplenic T-cell lymphomas (evidence: low; recommendation: do, weak). Except for ALK+ ana-
plastic large-cell lymphoma and elderly unﬁt patients, consolidation with high-dose chemotherapy was recommended
(evidence: low; recommendation: do, weak). 50 Gy radiotherapy was the recommended ﬁrst-line therapy for localized extra-
nodal T/NK-cell lymphoma nasal type (evidence: low; recommendation: do, strong), while L-asparaginase-containing chemo-
therapy regimens were recommended for patients with systemic disease (evidence: very low; recommendation: do, strong).
Conclusion: In adult T/NK-cell lymphomas, GRADE methodology was applicable to a limited number of key therapeutic
issues. For the remaining key issues, due to lack of appraisable evidence, recommendations was based on consensus meth-
odology.
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introduction
The Italian Society of Hematology (SIE), and the afﬁliate soci-
eties SIES (Società Italiana di Ematologia Sperimentale) and
GITMO (Gruppo Italiano Trapianto Midollo Osseo) have estab-
lished to produce guidelines for the most relevant hematological
issues. In this article, we report the results of the project of prac-
tice guidelines for the management of adult peripheral T- and
NK-cell lymphomas (PTCLs).
PTCLs account for about 12% of lymphoid malignancies [1].
PTCLs are rare disorders with a dismal prognosis and for which
few treatment options are available [2]. The WHO classiﬁcation
has divided this group of disorders into those with predomin-
antly leukemic from those with nodal, extranodal or cutaneous
presentation [1]. The present guidelines address speciﬁcally to
the management of non-leukemic adult PTCLs (Table 1).
methods
guidelines development process
The Advisory Council (AC), composed of three members with
expertise in clinical epidemiology, haematology and critical
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appraisal, oversaw the process. An Expert Panel (EP) was
selected according to the conceptual framework elements of the
NIH Consensus Development Program [3].
producing and grading evidence-based
recommendations
The AC selected the clinical questions that needed to be
addressed by a critical appraisal of evidence. The EP chose the
critical outcomes for each clinical query. Literature search was
limited to publications edited after 2005. The search included
proceedings 2010 through 2012 of the American Society of
Hematology, the European Hematology Association and the
11th International Conference on Malignant Lymphoma.
According to GRADE methodology [4], the AC prepared ‘evi-
dence tables’ and ‘quality-of-evidence tables’ for each critical ap-
praisal. The EP drafted recommendations based on the beneﬁt
to risk proﬁle of each compared intervention. Deﬁnite agree-
ment of the recommendations and their strength (weak or
strong) was made through subsequent face-to-face meetings.
Even though the recommendations were issued on the basis of
systematic review of literature published up to December 2012,
analysis of data published since that date up to September 2013
was carried out before publication of the present paper.
producing consensus-based recommendations
The consensus methodology was applied by the EP for all the
issues not addressable by a critical appraisal. During three con-
secutive consensus conferences, the issues were analysed and
discussed according to the nominal group technique, as previ-
ously described [5].
results
issue 1: diagnostic requirements (consensus-based
recommendations)
The characterization of pathological subtypes of PTCL is manda-
tory in order to optimize prognosis and therapy. The antibodies
raised against T-cell receptor (TCR) β and γ chains, are useful
for the differential diagnosis between αβ and γδ PTCLs. CD30
plays a basic role in the recognition of anaplastic large-cell lymph-
omas (ALCLs), CD30+ cutaneous lymphoproliferative disorder
(CTLPD) and the rare CD30+ PTCLs–NOS. ALCLs are further
distinguished in ALK+ and ALK− depending on the occurrence
or not of the t(2;5) translocation and variants. ALK− ALCL is
morphologically and phenotypically indistinguishable from the
ALK+ form; however, the distinction between the two entities is
of practical relevance, since the former behaves much better
than the latter [6]. CD16, CD56 and CD57 in variable combina-
tions and often in association with cytotoxic markers assist
in diagnosing NK-cutaneous lymphoma, hepatosplenic T-cell
lymphoma (HSTL), entheropathy-associated T-cell lymphoma
(EATL) type II and entheropathy-associated NK-cell lymphoma
(ENKTCL/NT).
Some other markers speciﬁcally have a prognostic values,
such as Ki-67 rate. Also the T-cell or NK-cell lymphomas
showing positivity of neoplastic cells for Epstein-Barr virus
(EBV) are characterized by a very aggressive behaviour. A vari-
able proportion of PTCLs–NOS, in fact, show positivity of
neoplastic cells for EBV. In 23 patients with PTCL nasal type
who underwent bone marrow (BM) biopsy for EBV, search
for EBV, especially by EBER in situ hybridization, was positive
in 10 [7]. A lower survival rate was seen in patients with BM
positive for EBER, suggesting that EBER positivity in BM is
the major determinant of a poor prognosis. Some markers,
such as t(6;7) andTP63 abnormalities, speciﬁcally allow to strat-
ify the prognosis of ALK− ALCL [8, 9].
Recommendations
The pathological diagnosis of NK/T-cell lymphomas requires the
integration of clinical data, morphology, immunohistochemistry, flow
cytometry, cytogenetics and molecular biology. This complex multi-
criteria diagnostic pathway translates into a high risk of misdiagnosis.
The referral of tissue specimens to national reference centres with high
expertise in the field is highly recommended.
The first diagnostic target is the assessment of the neoplastic nature of
a given T-cell population. Even though CD5 and CD7 are the most
frequently defective markers, the application of a larger panel from CD2
to CD8 antibodies is recommended (Table 2).
In cases with documented T-cell lymphoma, a subtype pathological
characterization is mandatory for prognostic and therapeutic reasons.
Such characterization is based on immunohistochemical and molecular
characterization.
Antibodies against the β and γ chains of the T-cell receptor (TCR) can
be usefully applied for the distinction of tumours derived from αβ and γδ
T-lymphocytes, respectively. The usage of antibodies against the ALK
protein is pivotal for the differential diagnosis between ALK+ and ALK−
anaplastic large-cell lymphomas (ALCL).
Besides immunohistochemical staining, the detection of clonal
rearrangement of the genes encoding for the TCR is pivotal for the
Table 1. Peripheral T- and NK cell neoplasms (excluding mature T-
cell leukaemias)
Nodal peripheral T-cell lymphomas (PTCL)
Peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS)
Angio-immunoblastic T-cell lymphoma (AITCL)
Anaplastic large-cell lymphoma (ALCL), anaplastic lymphoma
kinase (ALK) positive
Anaplastic large-cell lymphoma (ALCL), ALK negative
(provisional)
Extranodal PTCL
Extranodal NK-/T-cell lymphoma, nasal type
Enteropathy-associated T-cell lymphoma (EATL)
Hepatospleinic T-cell lymphoma (HSTL)
Subcutaneous panniculitis-like T-cell lymphoma (αβ only)
(SPTCL)
Cutaneous T-cell lymphoma (CTCL)
Mycosis fungoides (MF)
Sezary syndrome
Primary cutaneous CD30+ T-cell lymphoproliferative disease
Primary cutaneous PTCLs
WHO classification 2008 [1].
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distinction between partial lymph node involvement by peripheral T-cell
lymphoma (PTCL) and paracortical T-cell hyperplasia.
Immunohistological markers of aggressiveness are mandatory to better
characterize the prognostic classification of these lymphomas. The Ki-67
marking is included in the modified prognostic index for peripheral T-cell
lymphoma unspecified (PIT) (prognostic index for PTCL, not otherwise
specified) in which BM involved is substituted by a Ki-67 rate >80%.
The search for EBV is recommended. EBER should be carried out on
BM specimens of patients with nasal PTCL to identify the presence of
EBER positive cells, which appears to carry a poor prognosis.
issue 2: pre-treatment evaluation and staging
requirements (consensus-based
recommendations)
The International Prognostic Index (IPI) predicts the outcomes
in all PTCL subtypes by including age, serum lactic dehydrogen-
ase (LDH) levels, and performance status [10]. The index was
further reﬁned by the adjunct of BM involvement (PIT score)
[11] or Ki-67 (modiﬁed PIT score) [12]. The recently proposed
Glasgow Prognostic score [13], including C-reactive protein and
albumin assessment, is potentially useful for a better stratiﬁcation
in low-risk patients, however, still waits for validation. In the NK
subset of extranodal disease, high β2-microglobulin values and
EBV-DNA load are all unfavourable prognostic factors; however,
the standard stratiﬁcation is done according to Korean Prognostic
Index (KIPI), which also allows to predict CNS involvement
[14, 15] (Table 3).
Recommendations
After a diagnosis of PTCL, common clinical evaluations useful for staging
and prognostic assessment should include: physical examination and
performance status evaluation; complete blood count; biochemistry (liver
and kidney function tests, LDH, total serum proteins, protidogram).
Bone marrow trephine biopsy, contrast-enhanced whole-body CT scan,
Waldeyer ring examination and ear-nose-throat evaluation should be
carried out except for early (I and IIA stages) mycosis fungoides. In nodal
PTCL, pre-treatment evaluation should also include: serum
immunoglobulin assay and direct anti-globlin test.
In enteropathy-associated T-cell lymphoma (EATL), pre-treatment
evaluation should also include: test for coeliac disease and colonoscopy
with last ileum loop examination and random biopsies.
18F-fluorodeoxyglucose positron emission tomography/computed
tomography scanning is not routinely recommended. However, in patients
with nasal-type PTCL, PET is recommended since it was documented to
be a valuable modality for staging and treatment planning [16].
In erythrodermic cutaneous T-cell lymphoma (CTCL), T-cell
associated antigens (CD2, CD3, CD4, CD7, CD8, CD26) should be
evaluated in peripheral blood lymphocytes.
In all forms of PTCL except for CTCL, Ann Arbor staging should be
used to define disease extension. In CTCL, the ISCL-EORTC system
should instead be used.
IPI prognostic index should be used for nodal PTCL. For PTCL, a
specific Korean-IPI (KIPI) prognostic index has been proposed. PIT
prognostic index should also be used for PTCL-NOS.
issue 3: ﬁrst-line therapy in nodal T-cell lymphoma,
intestinal and hepatosplenic T-cell lymphomas
(evidence-based recommendations)
The Panel devised the following key questions to be analysed
according to GRADE appraisal of evidence.
For patients with nodal, intestinal and hepatosplenic T-cell
lymphoma, is there a therapy better than cyclophosphamide,
doxorubicin, vincristine and prednisone (CHOP) in ameliorating
complete response (CR) and progression-free survival (PFS) pro-
vided that an acceptable toxicity was assured?
Table 3. Prognostic index in peripheral T-cell lymphomas
IPI (all patients) K-IPI PIT
Factors
1) Age (≤60 versus >60
years)
2) Serum LDH
(≤1 × normal versus
>1 × normal)
3) Performance status
(0 or 1 versus 2–4)
4) Stage (I or II versus
III or IV)
5) Extranodal
involvement (≤1 site
versus >1 site)
Factors
1) B symptoms
2) Stage ≥3
3) LDH level
>1 × upper
normal limit
4) Regional lymph
nodes (N1–N3,
not M1)
Factors
1) Age >60 years
2) ECOG PS ≥2
3) LDH level more
than
1 × normal
value
4) BM
involvement
Index Index Index
Low = 0 or 1 Group 1: no
adverse factors
Group 1: no
adverse factors
Low intermediate = 2 Group 2: 1 factor Group 2: 1 factor
High intermediate = 3 Group 3: 2 factors Group 3: 2 factors
High = 4 or 5 Group 4: 3 or 4
factors
Group 4: 3 or 4
factors
Table 2. List of markers applicable to formalin-fixed, paraffin-
embedded tissue sections for the diagnosis of peripheral NK/T-cell
lymphomas
Markers
T cell CD2, CD 3, CD 4, CD5, CD7, CD8,
CD52, βF1, TCRγ
Cytotoxic TIA1, granzyme B, perforin
FTH (follicular helper
T cell)
CD10, Bcl6, PD1, CXCL13, SAP, ICOS,
CCR5
Treg FoxP3
NK CD16, CD56, CD57
Activation CD25, CD30
Proliferation MIB1/Ki67
B cell CD20, BSAP/PAX5
EBV EBER ISH (in situ hybridization),
LMP1, EBNA2
Follicular dendritic cells CD21
Histiocytes and epiteliod
elements
CD68/PG-M1
Others CCR4, ALK, EMA, CD45
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According to a meta-analysis of studies in patients with PTCL
treated with anthracycline-based regimens, 2-year event-free
survival (EFS) of 38% is expected after standard CHOP and
5–10% toxic mortality [17]. Only two regimens proved weak
evidence of superiority to CHOP for ﬁrst-line treatment:
etoposide-enhanced CHOP in young or ALK+ patients, and in-
tensiﬁed induction with ifosfamide, vepeside and epirubicin
plus methotrexate followed by upfront autologous stem cell
transplantation (ASCT) in EATL [18]. Four studies, including
two randomized trials, compared etoposide containing CHOP
versus CHOP [19–22]: no advantage in OS was ever detected.
However, amelioration of PFS by 10%–20% in patients aged <60
years and ALK+ was reported [21] versus a higher grade 3–4
toxicity and hospitalization in the elderly [20]. Indirectness and
mild inconsistency in the CR and PFS outcomes caused the evi-
dence be judged of low quality. However, the EP judged that the
beneﬁt-to-risk balance in young patients was favourable.
The adjunct of bleomicin to CHOP (ACVBP) was judged to
be inferior to CHOP due to a twice as high toxic mortality with
ACVBP, especially in elderly patients and in those with a poor
performance status, as reported by two phase II studies [23, 24].
Therefore, the EP judged that the survival beneﬁt, i.e. improved
EFS and OS, reported in the 60- to 70-year subgroup could not
balance the higher toxicity over CHOP, and provided recom-
mendation against ACVBP (evidence very low).
Uncertainty was reported by the EP regarding ﬁrst-line
CHOP14 when compared with CHOP21 [21], since EFS amelior-
ation was documented in both old and young low-risk patients
without a relevant increase of toxicity. However, the advantage was
not judged clinically relevant and the quality of evidence was low
due to inconsistency, imprecision and indirectness of the unique
study addressing this comparison. Similarly, no evidence is avail-
able supporting a preference for eight versus six CHOP courses.
Evidence regarding the combination of CHOP with alemtu-
zumab consists of four phase II studies [25–28]. No consistent
demonstration of improved survival could be inferred. A vari-
able CHOP14 or CHOP21 and six or eight cycles schedule were
applied; therefore, the overall quality of the evidence was judged
to be very low due to limitations and imprecision. A NCI trial
with low number of patients reported a survival plateau with
dose-adapted etoposide, vincristine, doxorubicin, cyclophos-
phamide, prednisone (EPOCH) and Campath [29]. The EP
could not reach a consensus on the beneﬁt-to-risk-ratio of C-
CHOP for ﬁrst-line therapy.
Evidence was insufﬁcient to support any recommendation
regarding the adjunct of denileukin diftitox [30] or bortezomib
[31] to CHOP, as well as gemcitabine to CHEOP [32].
In summary, the EP agreed that CHOP remains the standard
chemotherapy for nodal, intestinal and hepatosplenic T-cell
lymphoma. Exception could be etoposide-containing CHOP in
young patients and those with ALK+ lymphomas (evidence:
low; recommendation: do, weak). The adjunct of bleomicin to
CHOP induces a high toxicity not balanced by increased effect-
iveness (evidence: low; recommendation: do not do, weak).
For young patients (<65 years old) with nodal, intestinal and
hepatosplenic T-cell lymphomas is frontline autologous stem cell
transplantation (ASCT) better than standard chemotherapy?
We identiﬁed eight prospective studies applying consolidation
ASCT in at least 15 PTCL patients achieving a ﬁrst complete
remission [11, 33–40], and some retrospective studies enrolling
>50 patients [41–45]. A small randomized study compared dif-
ferent induction regimens [11], while a second one compared
chemotherapy (ACVB or NCVB) with versus without consoli-
dation ASCT [38]. With the former, a higher toxicity and lower
survival with megaCHOEP when compared with cyclophospha-
mide, doxorubicin, vincristine, etoposide and prednisone
(CHOEP) induction was found. With the latter, higher but not
statistically signiﬁcant survival rates were reported with ASCT
consolidation. A non-statistically signiﬁcant trend was also
reported by a retrospective case–control study by GELA [44]. A
retrospective study addressed to EATL reporting 26 patients
treated with IVE/MTX-ASCT regimen: EFS and OS were signiﬁ-
cantly better in patients assigned to intensive versus standard
anthracycline-based therapy [18]. One retrospective study [45]
reported lower relapse rate by the use of TBI.
The EP agreed that in young patients with nodal, intestinal
and hepatosplenic T-cell lymphomas, frontline ASCT was better
than standard chemotherapy (evidence: very low; recommenda-
tion: do, weak). Results cannot be extrapolated to patients aged
over 65 years or with ALK+ ALCL.
Recommendations
The enrolment into clinical trials with new and experimental drugs
should be highly recommended in patients with PTCL.
In patients aged 65 years or younger, with nodal, intestinal or
hepatosplenic T-cell lymphoma, except for ALK +ALCL, six courses of
CHOP or CHOEP (induction phase) followed by ASCT (consolidation
phase) is the recommended therapy.
For ALK+ ALCL patients with an IPI score < 3, the induction phase
with CHOP or CHOEP × 6 courses without the consolidation phase is
recommended.
Patients older than 65 years, CHOP or CHOP-like regimens are the
first therapeutic options. In patients fit to intensive chemotherapy, the
approach used in younger patient can be considered.
issue 4: ﬁrst-line therapy in extranodal PTCL nasal
type (evidence-based recommendations)
For patients with disseminated extranodal PTCL nasal type, is
there a ﬁrst-line chemotherapy better than CHOP, i.e. ameliorat-
ing CR and PFS provided that an acceptable toxicity was assured?
Etoposide-based regimens such as EPOCH or etoposide, ifos-
famide, cisplatin, dexamethasone did not prove to increase CR
or PFS, the critical end points selected by the EP for evidence
evaluation [46]. Enhancement of CHOP/CEOP with oral nitro-
sureas in limited-stage patients provided prolonged PFS in a
retrospective study [47], but the data were not conﬁrmed by a
randomized phase II study [48]; therefore evidence was not con-
sidered conclusive.
A L-asparaginase-based regimen (SMILE) was applied upfront
to 38 advanced-stage patients enrolled in a phase II trial: short-
term OS was 55% [49] which is promising when compared with
historical data [50–52].
On the basis of the reported evidence, the EP agreed that
L-asparaginase-containing regimens such as SMILE or Aspa-
Met-Dex [53] can obtain better response rates (RRs) and PFS
than CHOP (evidence: low; recommendation: do, strong).
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However, the toxicity of SMILE is so high that it should not be
used without optimal supportive care.
For patients with limited-stage PTCL nasal type is combined
chemioradiotherapy (CRT) better than CT or radiotherapy (RT)
alone in providing a CR, provided that an acceptable toxicity was
assured?
All of the studies allowing comparisons among treatments
were retrospective. RT 50 Gy alone achieved 69% PFS in stage I
patients [54, 55], which corresponded to a relevant improve-
ment of survival rate (from 15%–27% to 50%–83% at 5 years)
when compared with CT alone [56].
RT doses >50 Gy achieved better survival rates at regression
analyses [57–61]. Higher doses inevitably increased toxicity [62];
however, grade 3–4 adverse events are usually not reported [63].
RT followed by CT signiﬁcantly improved RR and survival
versus CT alone in three retrospective studies in patients with
limited-stage disease [57, 58, 64]. Results from retrospective
studies are not consistent with the survival advantage of CRT
when compared with RT alone [61, 65, 66]. However, in the
largest retrospective cohort [57] and recent studies [67, 68],
median survival duration was signiﬁcantly longer in patients
treated with CRT (72 versus 42 months). Patients with CR
achieved a survival rate of 80% at 5 years [63]: therefore, CR
appears to be a robust intermediate end point in this setting.
In stage I patients, RT achieved better survival rates (90%
versus 49% at 5 years) when applied upfront rather than after CT
[58], but a recent phase II study conﬁrmed satisfactory survival
rates (75% at 5 years) with EPOCH CT followed by involved ﬁeld
radiotherapy [46] in localized nasal extranodal NK lymphoma.
Similar data (survival rates >78% at 2–3 years) were reported by
two phase I/II studies applying concurrent RT [67–70] and CT
with various agents including etoposide, ifosfamide, vincristine,
L-asparaginase and platinum. Despite such favourable results, no
comparison of schedules including concurrent or subsequent RT
was conducted versus CT alone. Moreover, several studies
reported high rates of progression during (anthracycline-based)
CT not preceded by RT. Therefore, the EP favoured the classic
upfront schedule.
On the basis of the above reported evidence, the essential
treatment modality in limited-stage NK/T-cell lymphoma nasal
type is RT which is signiﬁcantly more effective than CT (evi-
dence: very low; recommendation: do, weak). It should be used
at doses higher than those usually employed in lymphoma, of
50–54 Gy, and it should be given upfront and not after CT. The
beneﬁt of adding CT either concurrently or after RT is less
proven, particularly in localized disease.
In patients with extranodal PTCL nasal type, does haemato-
poietic stem cell transplantation (HSCT) prolong PFS or overall
survival (OS)?
A few reports analysed high-dose CT in the subset of PTCL
nasal type [71]. Retrospective data on allogeneic stem cell trans-
plantation (allo-SCT) in refractory/relapsed patient support its
feasibility and potential beneﬁt [72–77].
The Panel agreed on claiming that ASCT carried out in
patients with bad prognostic features during complete remission
may prolong survival. Allo-SCT can rescue a proportion of
patients with chemosensitive relapse (evidence: very low; recom-
mendation: uncertain).
Recommendations
The treatment of PTCL nasal type differs according to the extent of the
disease. Patients with localized disease should receive radiotherapy as
early as possible at doses of at least 50 Gy to the tumour and adjacent
structures
The evidence is not sufficient to routinely support CT concurrently or
sequentially to RT.
Patients with systemic disease should receive L-asparaginase-
containing regimens. The SMILE protocol proved to produce the best
results, although toxicity was not negligible.
The use of autologous HSCT should be considered during first
complete remission.
RT should be added to areas of bulky or residual disease.
issue 5: ﬁrst-line therapy in panniculitis
(consensus-based recommendations)
For patients with panniculitis, is chemotherapy better than local
radiotherapy, i.e. ameliorating PFS provided that an acceptable
toxicity was assured?
Published case series of panniculitis never exceed 20 patients,
and they do not distinguish αβ from γδ entities [78]. An array of
treatments have been successfully applied: pulse steroids [79],
bexarotene [80], cyclosporine [81, 82], methotrexate, anthracy-
cline-based chemotherapy [83, 84], romidepsin [85]. RT was
judged a reliable therapeutic option for localized disease, mostly
Table 4. Novel agent response data in relapsed T-cell lymphoma
Regimen (reference) No. of patients Response PFS (months) OS
Bendamustine (Damaj et al.) [107] 38 ORR, 47%; CR, 29% NR NR
Pralatrexate (O’Connor et al.) [108] 111 ORR, 29%; CR, 11% Median, 3.5 Median, 14.5 months
Romidepsin (Coiffier et al.) [109] 130 ORR, 25%; CR, 15% Median, 4
DHAP–alemtuzumab plus auto-SCT (Kim et al.) [110] 24 ORR, 50%; CR, 21% NR Median, 6 months
Gem–Cis–methylpred (Arkenau et al.) [111] 16 ORR, 69%; CR, 19% NR 69% at 1 year
PEGS (Mahadevan et al.) [112] 33a ORR, 39% 12% at 2 years 30% at 2 years
Lenalidomide (Dueck et al.) [113] 23 ORR, 30% Median, 3.2 Median, 8 months
Zancolimumab (D’Amore et al.) [114] 21 ORR, 24% NR NR
aSeventy-nine percent were newly diagnosed.
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Table 5. Recommendations published in the last 5 years for the management of NK/T-cell lymphomas
BJH, 2011 [117] ESMO, 2013 [118] SIE, SIES, GITMO, 2014
Nodal T-cell
lymphoma,
intestinal and
hepatosplenic
T-cell lymphoma
Peripheral T-cell lymphoma, not otherwise specified
(PTCL-NOS): CHOP remains the standard therapy.
Consideration should be given to consolidation with
auto-haematopoietic stem cell transplantation (HSCT).
Relapsed or refractory disease should be treated with
relapse-schedule chemotherapy and considered for
allo-HSCT.
CNS prophylaxis should be considered
Angioimmunoblastic T-cell lymphoma (AITL): Outside a
clinical trial, CHOP or FC would be considered as
standard therapy. Consolidation with auto-HSCT should
be considered for chemosensitive diseases in first
remission or after relapse. Routine CNS prophylaxis is
not warranted.
ALCL (anaplastic large-cell lymphoma): Patients with
limited-stage ALCL and no adverse prognostic features
by IPI should be treated with three to four cycles of
CHOP chemotherapy and involved field radiotherapy.
All other patients should receive six to eight cycles of
CHOP chemotherapy. ALK-negative patients should be
treated as for PTCL-NOS. Primary cutaneous ALCL
(ALK negative) should be managed with local
excision ± radiotherapy and chemotherapy reserved for
those patients with systemic disease. At relapse, patients
should receive platinum-based chemotherapy or an
alternative salvage regimen and patients with
chemosensitive disease should be considered for
transplant.
Enteropathy-associated T-cell lymphoma (EATL): CHOP
like therapy, with or without an up-front autograft
remains a common approach outside trial but evidence
of efficacy is lacking and adoption of a more intensive
approach, such as NCRI/SNLG protocol, is a reasonable
option in fitter patients.
First-line treatment of all TCL subtypes but NK/TCL,
nasal type, should be based on anthracycline-
containing regimens such as CHOP/CHOEP and
CHOP-like regimens. An exception to this
assumption could probably made for EATL that has
been treated with a specific regimen according to the
Scottish Lymphoma Group. For patients with poor-
risk TCL (IPI or PIT ≥2) with a chemosensitive
disease (in CR or PR) after induction chemotherapy,
autologous stem cell transplantation (ASCT) should
be delivered.
Second-line treatment of refractory/relapsed TCL should
contain one or more than one among the following
drugs: platinum, gemcitabine. Auto-SCT should be
considered for relapsed/refractory TCL-NOS as well
as ALK-negative ALCL and AITL.
Allo-SCT in relapsed/refractory TCL (TCL-NOS, ALCL
ALK− and AITL) proved to be the only curative
treatment of this patient subset (provided by
retrospective studies).
Refractory relapsed TCL should be enrolled, whenever
possible, in phase I or II prospective clinical trials
aimed at exploring the efficacy of new drugs that have
shown activity in preclinical studies.
In patients aged 65 years or younger, with nodal,
intestinal or hepatosplenic T-cell lymphomas,
except for ALK+ ALCL, six courses of CHOP or
CHOEP (induction phase) followed by ASCT
(consolidation phase) is the recommended therapy.
For ALK+ ALCL patients with an IPI score lower than
3, the induction phase with CHOP or CHOEP × 6
courses without the consolidation phase is
recommended.
Patients older than 65 years, CHOP or CHOP-like
regimens are the first therapeutic options. In
patients fit to intensive chemotherapy, the approach
used in younger patient can be considered.
In patients with refractory or relapsed PTCL (excluding
ALC), platinum-based, ifosfamide-based,
gemcitabine-containing chemotherapy, pralatrexate,
romidepsin or bendamustine are the recommended
therapies.
The current evidence does not allow to make a choice
among these agents.
In refractory or relapsed ALCL, anti-CD30
(brentuximab–vedotin) monoclonal antibody
should be preferred.
Patients with chemosensitive disease should receive
consolidation with allogeneic SCT. In the absence of
a donor, autologous transplantation can be used.
In non-transplant eligible patients, novel agents should
be recommended, but these therapies should be
considered as experimental and to be done within
clinical trials.
Hepatosplenic T-cell lymphoma: allogeneic bone marrow
transplantation could be considered but the evidence is
purely anecdotal. Conventional chemotherapy
approaches as for PTCL-NOS are the default, and there
are some survivors reported in the literature.
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Extranodal NK/T-
cell lymphoma,
nasal type
Patients with localized disease should receive radiation with
50–55 Gy. The value of additional chemotherapy (CHOP,
etoposide-based or asparaginase-based) remains unclear
but is considered conventional pending more
information. Asparaginase-containing regimens should
be considered in relapsed or refractory disease. High-dose
therapy is unproven, and there is no basis to recommend
it outside trial.
For NK/T-cell nasal-type lymphoma, the treatment
should include L-asparaginase and local
(nasopharyngeal) radiotherapy.
Patients with localized disease should receive
radiotherapy as early as possible at doses of at least
50 Gy to the tumour and adjacent structures. The
evidence is not sufficient to routinely support CT
concurrently or sequentially to RT. Patients with
systemic disease should receive L-asparaginase-
containing regimens. The SMILE protocol proved to
produce the best results, although toxicity was not
negligible. The use of ASCT should be considered
during first complete remission. Radiotherapy
should be added to areas of bulky or residual disease.
Subcutaneous
panniculitis-like
T-cell lymphoma
(SPTCL) (αβ only)
CHOP-like chemotherapy appears to be effective and
produces survivors.
Relapse disease may respond to dose intensification in some
patients. Local radiotherapy has a place for good
prognosis localized symptomatic skin involvement which
does not resolve with topical steroids.
In SPTCL without associated haemophagocytic
syndrome (HPS), systemic steroids or other
immunosuppressive
Agents should be considered first, whereas in cases of
solitary or localized skin lesions, radiotherapy with
electrons is advised. Little information on radiation
dose is available, but a dose of 40 Gy has been used.
Bexarotene may be also effective in SPTCL. Multi-
agent chemotherapy is required only in cases with
progressive disease not responding to
immunosuppressive therapy or in cases with HPS.
Radiotherapy (20–30 Gy), possibly preceded by
reductive surgery, should be recommended in
patients with localized lesions. Pulse steroid therapy
(0.6–0.7 mg/kg/die × 10 days every month
prednisone or equivalent) should be recommended
in patients with multiple non-contiguous lesions.
Six courses of monochemotherapy with gemcitabine or
peg-doxorubicin is an alternative option in patients
with high tumour load.
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based on evidence from CTCL. The EP judged that the scant lit-
erature could not support evidence-based recommendations.
Recommendations
Radiotherapy (20–30 Gy), possibly preceded by reductive surgery, should
be recommended in patients with localized lesions.
Pulse steroid therapy (0.6–0.7 mg/kg/die ×10 days every month
prednisone or equivalent) is recommended in patients with multiple
non-contiguous lesions.
Six courses of monochemotherapy with gemcitabine or peg-
doxorubicin is an alternative option in patients with high tumour load.
issue 6: ﬁrst-line therapy in advanced CTCL
(consensus-based recommendations)
Several large retrospective studies consistently documented clin-
ical RRs with total skin electron beam irradiation (TSEBI), i.e.
ionizing radiation to the entire skin surface. as high as 100% in
T2/T3 mycosis fungoides (MF) with relevant improvement of
symptoms and quality of life [86–90], and short response dur-
ation in T3 MF with cosmetic adverse effects.
Cytotoxic regimens has been proven to prolong OS in
advanced-stage CTCL; therefore, immunomodulatory therapies are
preferred for ﬁrst-line systemic treatment. Interferon alpha-2b
achieves 60%–100% RR in stage IIB–IVA disease: higher rates are
allowed by the association with psoralens plus ultraviolet A [91].
Bexarotene did not prove to achieve better RRs than CT [92].
Indeed, with gemcitabine monotherapy a 68% RR has been
reported both in untreated and in refractory patients with advanced
CTCL [93]. Similar or higher rates were obtained with pegylated
liposomal doxorubicin [94, 95]. Polychemotherapy never produced
higher RRs than the above monochemotherapy regimens [96].
Extracorporeal photophoresis (ECP) produced RRs of 30%–
70% which were greatly increased with the association with
interferon, bexarotene or granulocyte-macrophage-colony
stimulating factor [97–99]. However, the evidence that ECP
improves both RRs and OS in the setting of refractory erythro-
dermic CTCL was judged of low quality [100]; therefore, the EP
did select ECP as a ﬁrst-line treatment.
Three histone deacetylase (HDAC) inhibitors were tested:
romidepsin, vorinostat and denileukindiﬁtox. The former
achieved RRs of 34% in two large phase II studies [101, 102].
Both vorinostat and denileukin diftitox achieved 30%–44%
responses in a phase III and some phase II trials [103–105].
A recent literature review retrieved scant retrospective data on
allo-SCT in advanced CTCL [105] and no randomized study.
However, retrospective data consistently showed [106] survival
rates >50% at 3 years with non-myeloablative conditioning.
Recommendations
Total skin electron beam irradiation (TSEBI) ± boost is highly
recommended first-line in skin-advanced cutaneous T-cell lymphoma.
Monochemotherapy is an alternative option in case TSEBI facilities are
not readily available.
Different drugs have been proposed for this indication (gemcitabine,
peg-doxorubicin, vorinostat, romidepsin, denileukindiftitox, bexarotene),
but there is no evidence of superiority for any of them.
Bexarotene should be recommended in patients refractory to or
relapsing after first-line systemic treatment, and should also be used in
patients obtaining at least stabilization after TSEBI or CT first line.
Enrolment in clinical trials should be recommended whenever possible.
Young patients responding to first-line treatment should be considered,
at least in selected cases, for HSCT procedures.
issue 7: monitoring the response to ﬁrst-line
therapy (consensus-based recommendations)
Recommendations
In PTCL, re-evaluation should be carried out after three cycles of
chemotherapy to define primary refractory disease.
In PTCL nasal type, the re-evaluation should be done after two cycles
of the SMILE regimen. EBV-DNA quantitative assay could be used
during treatment to predict therapy outcome.
In CTCL, re-evaluation should be done 6 weeks after the completion of
TSEBI or after three cycles of monochemotherapy.
PET/CT scan has been proposed as useful tool for early response
evaluation in PTCL, but it should be discouraged outside clinical trials
since no validated reporting rules are available.
issue 8: therapy for non-responding or relapsed
patients (consensus-based recommendations)
Relapsed/refractory disease is common for most patients with
PTCL who receive current agents with inadequate salvage
therapy. An array of new agents have been tested with early
phase trials in non-responding or relapsed patients. A number
has been proven to be effective (Table 4) [107–114].
The role of allo- and auto-transplantation in patients with
advanced disease has been retrospectively studied in 77 and 241
patients with PTCL [115, 116]. Three-year PFS and OS of ASCT
recipients beyond ﬁrst complete remission were 42% and 53%,
respectively. Among allo-SCT recipients who received transplanta-
tions beyond ﬁrst complete remission, 31% remained progression-
free at 3 years, despite being more heavily pre-treated and with
more refractory disease. Non-relapse mortality was 3.5-fold higher
for allo-SCT. In multivariate analysis, chemotherapy sensitivity and
two or fewer lines of pre-transplantation therapy were prognostic
of survival. These data suggest greater effectiveness of SCT earlier
in the disease course and limited utility in mutiply relapsed disease.
Recommendations
In patients with refractory or relapsed PTCL (excluding ALC), platinum-
based, ifosfamide-based, gemcitabine-containing chemotherapy,
pralatrexate, romidepsin or bendamustine are the recommended
therapies.
The current evidence does not allow to make a choice among these
agents.
In refractory or relapsed ALCL, anti-CD30 (brentuximab–vedotin)
monoclonal antibody should be preferred.
Patients with chemosensitive disease should receive consolidation with
allo-SCT. In the absence of a donor, ASCT can be used.
In non-transplant eligible patients, novel agents should be
recommended, but these therapies should be considered experimental and
to be done within clinical trials.
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discussion
In this project, we used a rigorous appraisal of evidence for pro-
viding speciﬁc evidence-based recommendations on manage-
ment of PTCL according to GRADE methodology. This system
was applicable to a limited number of issues in which a prelim-
inary judgement of the quality of evidence and a subsequent
assessment of the strength of the recommendation based on a
qualitative risk-beneﬁt analysis was provided [4]. For the
remaining key issues, we adopted the group discussion method-
ology and we provided consensus-based recommendations.
Few other guidance, projects have been published for these
rare lymphomas. The British Committee for Standards in
Haematology has produced in 2011 guidelines for the manage-
ment of mature T-cell and NK-cell neoplasms, excluding CTCLs
[117]. In 2013, the European Society of Medical Oncology
(ESMO) organized consensus conferences to focus on speciﬁc
issues in different lymphomas, including PTCL [118, 119]. The
recommendations on therapy are reported in Tables 5 and 6.
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